Core B provides common facilities and expertise for mechanistic interpretation of pathological and immunopathological studies. The broad, long range objective of the Immunopathology Core B is to provide insights into the mechanism of action of the therapeutic manipulations used to induce grafts survival and tolerance. The insights from these studies will complement the interpretation of clinical samples in patients on similar protocols, as has been our experience. The other goal will identify and evaluate any toxicities and complications that may arise from these treatments. The primary role of the pathological analyses is to document and characterize the status of the graft (nature of infiltrate, presence of acute or chronic rejection, including a humoral component) and the systemic effects of the protocols (toxicity, complications). The mechanistic studies to be done on protocol biopsies include detection of Treg cells in grafts and lymphoid organs, measures of local inflammation in the graft and infiltration and activation of various cell types important in allograft rejection (T memory, dendritic cells) and antibody/complement effects. These are described in detail in the three projects, n addition full necropsies will be performed to determine the efficacy and adverse effects of the novel treatment strategies. The techniques that will be utilized include routine histology, immunohistochemistry, immunofluorescence with specialized techniques available as needed (electron microscopy, laser capture). Immunoperoxidase techniques with a panel of mAbs will distinguish the infiltrating cell types, adhesion and cytokine molecules and receptors, and activation markers quantitated using digital imaging of whole slides. Immunofluorescence will be used to localize the deposition of immunoglobulin and complement, as well as phenotyping cells with double/triple staining. C4d stains will be used to detect humoral rejection. We have a well-annotated tissue bank of frozen and paraffin embedded tissue available from our previous transplantation experiments (>6000 samples), which can be drawn upon to expand and refine our analysis.
The pathology studies are essential to all of the projects to document graft acceptance or rejection, reveal toxicities or complications of the protocols and to provide a source of insights from the grafts and lymphoid organs on the mechanisms of action of the various therapeutic manuevers.
|Purroy, Carolina; Fairchild, Robert L; Tanaka, Toshiaki et al. (2017) Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival. J Am Soc Nephrol 28:2377-2392|
|Madsen, Joren C (2017) Advances in the immunology of heart transplantation. J Heart Lung Transplant 36:1299-1305|
|Wang, Zhaohui; Zheng, Qian; Zhang, Huiping et al. (2017) Ontak-like human IL-2 fusion toxin. J Immunol Methods 448:51-58|
|Zheng, Qian; Wang, Zhaohui; Zhang, Huiping et al. (2017) Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19+ tumors. Mol Oncol 11:584-594|
|Hotta, Kiyohiko; Aoyama, Akihiro; Oura, Tetsu et al. (2016) Induced regulatory T cells in allograft tolerance via transient mixed chimerism. JCI Insight 1:|
|Wang, Zhaohui; Navarro-Alvarez, Nalu; Shah, Jigesh A et al. (2016) Porcine Treg depletion with a novel diphtheria toxin-based anti-human CCR4 immunotoxin. Vet Immunol Immunopathol 182:150-158|
|Wang, Zhaohui; Pratts, Shannon G; Zhang, Huiping et al. (2016) Treg depletion in non-human primates using a novel diphtheria toxin-based anti-human CCR4 immunotoxin. Mol Oncol 10:553-65|
|Nuñez, Sarah; Moore, Carolina; Gao, Baoshan et al. (2016) The human thymus perivascular space is a functional niche for viral-specific plasma cells. Sci Immunol 1:|
|La Muraglia 2nd, G M; O'Neil, M J; Madariaga, M L et al. (2015) A novel approach to measuring cell-mediated lympholysis using quantitative flow and imaging cytometry. J Immunol Methods 427:85-93|
|Matthews, Kristin A; Tonsho, Makoto; Madsen, Joren C (2015) New-Onset Diabetes Mellitus After Transplantation in a Cynomolgus Macaque (Macaca fasicularis). Comp Med 65:352-6|
Showing the most recent 10 out of 31 publications